JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma

QR Code

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Nobukazu Fujimoto, Yosuke Miyamoto, Sae Wada, Katsuyuki Hotta, Toshiyuki Kozuki, Keisuke Aoe, Jun Sakurai, Michihiro Yoshida, Daijiro Harada
Format:	article
Langue:	EN
Publié:	BMJ Publishing Group 2021
Sujets:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/af8197ea96ff4fda8b8b228a37b81135
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
par: Cova E, et autres
Publié: (2019)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
par: Hiroto Yoneda, et autres
Publié: (2021)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
par: Camillo Porta, et autres
Publié: (2008)

Cytomegalovirus infection in malignant pleural mesothelioma.
par: DeVon Hunter-Schlichting, et autres
Publié: (2021)

Modern management of malignant pleural mesothelioma
par: Patel SC, et autres
Publié: (2016)

Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion
par: Takumi Kishimoto, et autres
Publié: (2021)

Integrated genomics point to immune vulnerabilities in pleural mesothelioma
par: Anca Nastase, et autres
Publié: (2021)

Malignant Pleural Mesothelioma Nodal Status: Where Are We at?
par: Sara Ricciardi, et autres
Publié: (2021)

Clinical staging of malignant pleural mesothelioma: current perspectives
par: Bonomi M, et autres
Publié: (2017)

The role of radiation therapy in the treatment of patients with pleural mesothelioma
par: Tatiana N. Borisova, et autres
Publié: (2021)

The therapeutic implications of the genomic analysis of malignant pleural mesothelioma
par: Marjorie G. Zauderer
Publié: (2021)

Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas’s Experience
par: Giuseppe Mangiameli, et autres
Publié: (2021)

Maculopapular erythema caused by previously used chemotherapy drugs after nivolumab treatment for malignant mesothelioma
par: Junko Kanai, et autres
Publié: (2021)

« J’me suis laissé presser comme un citron »
par: Samuel Lamoureux
Publié: (2021)

CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
par: Masayuki Watanabe, et autres
Publié: (2021)

Pleural mesothelioma: management updates and nursing initiatives to improve patient care
par: Lehto RH
Publié: (2014)

The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma
par: Valeria Ramundo, et autres
Publié: (2021)

Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
par: Yuna Blum, et autres
Publié: (2019)

A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma
par: Jamil MO, et autres
Publié: (2017)

Blocking the GITR-GITRL pathway to overcome resistance to therapy in sarcomatoid malignant pleural mesothelioma
par: Meilin Chan, et autres
Publié: (2021)

Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers
par: Granieri A, et autres
Publié: (2013)

Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
par: Susana Cedres, et autres
Publié: (2021)

Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma.
par: Alfonso Baldi, et autres
Publié: (2011)

MALAT1 promotes malignant pleural mesothelioma by sponging miR-141-3p
par: Wang Pei, et autres
Publié: (2021)

Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism
par: Chiara De Santi, et autres
Publié: (2017)

A novel PDX modeling strategy and its application in metabolomics study for malignant pleural mesothelioma
par: Zhongjian Chen, et autres
Publié: (2021)

Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden
par: Kari Hemminki, et autres
Publié: (2021)

Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.
par: Giuseppe Matullo, et autres
Publié: (2013)

CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells.
par: Shazia Jamal, et autres
Publié: (2014)

Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
par: Rei Hashimoto, et autres
Publié: (2021)

Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations
par: Sebastian Curcean, M.B.B.S., et autres
Publié: (2021)

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
par: Kiyoshi Minohara, et autres
Publié: (2021)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
par: Alexander N Shoushtari, et autres
Publié: (2021)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
par: Tetsu Tomonari, et autres
Publié: (2021)

Unresectable hepatoblastoma: current perspectives
par: Trobaugh-Lotrario AD, et autres
Publié: (2017)

Nivolumab-Induced Exocrine Pancreatic Insufficiency
par: Boudewijn Sweep, et autres
Publié: (2021)

Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score
par: Federica Grosso, et autres
Publié: (2021)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
par: Junji Furuse
Publié: (2008)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
par: Schuette W, et autres
Publié: (2017)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
par: Katsuhiro Yoshimura, MD, PhD, et autres
Publié: (2021)